📊 Research: Working the Oracle

Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...

Apr 11, 2026

STREET SHEET RESEARCH MEMBERS ONLY

Become a paying subscriber to read the rest and instantly access 3 TRADE IDEAS from TOP ANALYSTS with 30%+ UPSIDE every week.

Apr 4, 2026

•

2 min read

Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.

Apr 1, 2026

•

2 min read

The market may be missing a protein upgrade that favors eggs.